The Obesity Boom Just Flexed Its Full Power

One earnings report left little room for doubt about who’s winning the obesity race right now.

With demand accelerating and guidance moving higher, the latest results underline just how powerful this growth story has become.

Hidden Opportunity (Sponsored)

Turn Thousands Into Seven Fortunes

$1,000 in just seven stocks in 2004 could have turned into a million-dollar portfolio today…

Back then… one financial expert begged people to look at Nvidia -- when it was trading at just $1.10!

Now… he’s urging you to look at a new group of seven stocks…

Check this Out (The NEXT Magnificent Seven)  

Never Miss a Stock Recommendation Again!

We now send our dividend picks right to your phone via text, so you’ll get the same actionable moves without having to open your inbox.

👉 Click here to get our dividend picks by text and keep our content right at your fingertips.

Pharmaceuticals

Why Pfizer’s Weight Loss Push Hinges on Tolerability

Pfizer (NYSE: PFE) has released new mid-stage data for its monthly injectable obesity therapy PF-3944, showing sustained weight loss through 28 weeks.

The drug, acquired through Pfizer’s $10 billion Metsera deal, is designed to move patients from weekly injections to once-a-month dosing, a meaningful convenience upgrade in a crowded field. If you are tracking differentiation in obesity care, monthly dosing is the prize everyone wants.

The Dropout Reality

The data also surfaced the key risk. About one in ten patients discontinued treatment due to tolerability issues, a rate broadly in line with the GLP-1 class but more consequential as dosing stretches longer and exposure increases.

For you, this is where promise meets reality. Convenience only works if patients stay on therapy, especially as real-world use replaces tightly controlled trials.

Bigger Than One Drug

This update fits into a much larger plan. Pfizer expects to advance more than 20 obesity related programs over the next year, positioning metabolic disease as a future growth pillar as older drugs lose exclusivity.

If PF-3944 holds up, it strengthens the case that obesity care can move beyond weekly injections. If not, Pfizer may need to rethink dosing or combinations before launch. Either way, this phase decides whether you are looking at a durable platform or another promising idea that stalls before the finish line.

PFE currently trades at $27 and pays a dividend of $1.72 per share, a yield of 6.36%.

Aerospace

Lockheed Martin Turns Sniper Pods Into a Real-Time Battlefield Network

Lockheed Martin (NYSE: LMT) has completed a major upgrade to its Sniper targeting pod, transforming it from a single aircraft sensor into a fully networked combat system. The company recently demonstrated two-way data sharing between fighter jets, with live target information also streamed to a ground control station.

Instead of one aircraft finding, tracking, and engaging a target alone, multiple air and ground units can now operate from the same real-time picture.

Seconds Matter Now

That shift compresses the detection timeline from minutes to seconds. In modern conflicts, speed is survival. If you are thinking about how wars are actually fought today, shared targeting changes everything. Assets no longer wait their turn; they move in parallel.

Old Fleets, New Tricks

The upgrade was shown on existing aircraft and does not require airframe modifications. That means operators can unlock networked warfare across current fleets rather than wait for next-generation platforms. Built on secure, mobile networks, the system stays resilient even when links are disrupted, a must in contested environments.

This is software turning legacy hardware into force multipliers. Lockheed is extending the life and relevance of widely deployed systems, and that is why you should see this as more than an upgrade. It is a shift in how targeting systems participate in the fight.

LMT currently trades at $613 and pays a dividend of $13.80 per share, a yield of 2.25%.

Breakthrough Tech (Sponsored)

Breakthrough Satellite Tech IPO Opportunity

A major tech company is preparing for what could become the largest IPO in history—and early investors are already positioning themselves for what’s next.

According to new research, a breakthrough project could soon connect billions of devices worldwide through ultra-fast satellite technology—unlocking an opportunity valued at over $2 trillion.

And here’s the surprising part: you don’t need insider access or accredited status to get involved.

You can take part using a regular brokerage account for less than $100.

[Click Here to See the Full Story]

*This ad is sent on behalf of Paradigm Press, LLC, at 1001 Cathedral St., Baltimore, MD 21201. If you're not interested in this opportunity from Paradigm Press, LLC, please click here to remove your email from these offers.

Athletic Apparel

Nike Pulls ACG Back From the Street and Into the Wild

Nike (NYSE: NKE) is quietly repositioning its All Conditions Gear line, and the signal matters. ACG was created to serve real outdoor use, but over time it drifted into streetwear and gorpcore culture, gaining visibility while losing technical clarity.

That tradeoff delivered hype, but it also blurred purpose. ACG became something worn more on sidewalks than on trails.

Function Over Flex

The renewed direction indicates Nike is recentering ACG on utility, durability, and performance-led design. Instead of chasing fashion cycles, the brand is leaning back into engineering credibility, materials, and real-world use cases.

If you are tracking Nike’s broader reset, this fits a shift toward sport, function, and long-term trust rather than trend-driven volume.

A Signal, Not a Sideshow

ACG is not just a product refresh; it is a message. Outdoor and technical categories reward authenticity and consistency, and demand tends to hold up better than fast lifestyle drops. For anyone watching closely, this reads as Nike choosing depth over noise. ACG’s roots in experimentation and problem-solving align with where the brand needs momentum to rebuild.

If executed well, the line proves that Nike is willing to course-correct. That is why you should see this less as nostalgia and more as intent, Nike reminding the market what it wants to stand for again.

NKE currently trades at $63 and pays a dividend of $1.64 per share, a yield of 2.57%.

TPG has increased its dividend payment to 61 cents, a growth of 35.56%. Its new yield is 4.56%.

TRI has raised its dividend to 65 cents, a boost of 10.08%. Its yield is now 2.97%. 

HSY has increased its dividend to $1.45, up 5.99%. Its new yield is 2.59%. 

ALL has raised its dividend to $1.08, a 8.00% increase, yielding 2.09%. 

GSK has boosted its dividend to 48 cents, an increase of 16.43%, with a yield of 3.38%.

GBDC has cut its dividend to 33 cents, a 15.38% drop. Its new yield is 10.64%.

Market Edge (Sponsored)

Analysts Flag Five Bullish Setups

A new research report highlights 5 stocks with the strongest potential to double in the year ahead.

Each was selected from thousands of companies and shows a rare mix of:

• Strong fundamentals

• Bullish technical setups

Past versions of this report delivered gains of +175%, +498%, and even +673%¹ — and the latest edition is free for a short time.

Available only until MIDNIGHT TONIGHT.

Download the free report

Everything Else

• Jeep, Ram, and Chrysler will stay under one roof, Stellantis CEO Antonio Filosa says, after rejecting calls to split up the company to improve performance. 

• Taco Bell brought the spice for Yum Brands in Q4; its same-store sales increased by 7%, with domestic market share growth driven by a broad spectrum of diners.

• Cosmetics firm Estée Lauder says it expects its profits to be about $100 million lower this year due to the impact of trade tariffs, even as it raised its fiscal 2026 outlook. 

• GM’s South Korean subsidiary has been instructed to increase production by around 8.5% this year to meet growing export demand, particularly for its Trax and Trailblazer models. Much of that demand comes from the US itself, the company says.